KAFTRIO 37.5 mg/25 mg/50 mg, film-coated tablet 56 tablets
Active ingredients: Ivacaftor, Tezacaftor, Elexacaftor
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet56 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KAFTRIO 37,5 mg/25 mg/50 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) polychlortrifluoroéthylène PVC papier aluminium suremballée(s)/surpochée(s) de 56 comprimés
- Marketing authorisation holder
- VERTEX PHARMACEUTICALS (IRELAND)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69275098CIP73024279CIP133400930242797Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉLEXACAFTORcomprimé | 50 mg · un comprimé | SA |
| TEZACAFTORcomprimé | 25 mg · un comprimé | SA |
| IVACAFTORcomprimé | 37,5 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.